Answer
Patients with porphyria or a family history of porphyria should be closely monitored during GONAL-f (follitropin alfa) treatment, and deterioration or first appearance of porphyria may require stopping treatment.
Sources for this answer
- GONAL-f 75 IU (5.5 micrograms)Merck · emc · SmPC §4.4 Special warnings and precautions for use · Version 19Document updated
Sources checked